IP Library › Granted Patent US 12,708,695
Granted Patent B2
US 12,708,695 · App. 18/612,434 · Granted Aug 18, 2026

Soft tissue adhesive composition of alpha-TCP and phosphorylated amino acid

Inventors: Philip Procter (Divonne les Bains, FR); Håkan Engqvist (Uppsala, SE); Michael Pujari-Palmer (Uppsala, SE); Gerard Insley (Limerick, IE)
Assignee: BIOMIMETIC INNOVATIONS LIMITED
A61L24/0031A61L24/0084A61L24/02A61L27/54A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,708,695
App. No.
18/612,434
Filed
Mar 21, 2024
Granted
Aug 18, 2026
Kind
B2
Art Unit
1615
USPC
424/400
Abstract

The present invention relates to a soft tissue adhesive comprising an aqueous composition comprising α-TCP and a phosphorylated amino acid. The composition has improved mechanical strength and is easily applied to the tissue.

Claims (16)

1 . A method of adhering a first soft tissue to a second soft tissue using a tissue adhesive comprising an aqueous solution, α-TCP, and a phosphorylated amino acid, wherein the tissue adhesive does not comprise a silicate compound, wherein the method comprises:

a. applying the tissue adhesive to the first soft tissue or to the second soft tissue and optionally leave it for a suitable period of time;

b. bringing the first tissue and the second tissue into contact with each other;

c. optionally applying a pressure on the first and second tissue for a suitable period of time; and

d. letting the tissue adhesive cure;

wherein the amount of phosphorylated amino acid is 40-90 wt % of the solid content.

2 . The method according to claim 1 wherein the steps are performed in vitro.

3 . The method according to claim 1 wherein the amount of the phosphorylated amino acid is 60-80 wt %.

4 . The method according to claim 1 wherein at least 95 wt % of the tissue adhesive comprises the aqueous solution, α-TCP and the phosphorylated amino acid.

5 . The method according to claim 1 wherein at least 98 wt % of the tissue adhesive comprises the aqueous solution, α-TCP and the phosphorylated amino acid.

6 . The method according to claim 1 wherein at least 98 wt % of the tissue adhesive comprises the aqueous solution, α-TCP and wherein the amount of phosphorylated amino acid is 60-80 wt %.

7 . The method according to claim 1 wherein the phosphorylated amino acid is phosphorylated serine.

8 . The method according to claim 1 wherein the aqueous solution is water.

9 . The method according to claim 1 wherein the tissue adhesive further comprises a hydrogel.

10 . The method according to claim 1 wherein the tissue adhesive further comprises collagen.

11 . The method according to claim 1 wherein at least one of the first and the second soft tissue is selected from tendon, ligament, fascia, skin, fibrous tissue, muscle, fat, nerve or blood vessel.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2024
From: PROCTOR, PHILIP; ENGQVIST, HÅKAN; PUJARI-PALMER, MICHAEL; INSLEY, GERARD; GPBIO LIMITED
To: BIOMIMETIC INNOVATIONS LIMITED
Reel/Frame 067066/0466 →
Priority Claims (2)
SE 1651271-7 · Sep 27, 2016 · national
SE 1651727-8 · Dec 22, 2016 · national
Continuity (2)
Continuation 16337350 · Sep 27, 2017
Related Publication 20240226370A1 · Jul 11, 2024
References Cited (37)
US 6533821B1 · Lally · 2003 [cited by applicant]
US 8105086B2 · Asgary · 2012 [cited by applicant]
US 11247941B2 · Hess et al. · 2022 [cited by applicant]
US 11638777B2 · Hess et al. · 2023 [cited by applicant]
US 20050217538A1 · Reinstorf et al. · 2005 [cited by applicant]
US 20090087390A1 · Modi · 2009 [cited by applicant]
US 20100121459A1 · Garigapati et al. · 2010 [cited by applicant]
US 20110277931A1 · Garigapati et al. · 2011 [cited by applicant]
US 20120288446A1 · Garigapati et al. · 2012 [cited by applicant]
US 20130122057A1 · Garigapati et al. · 2013 [cited by applicant]
US 20200030483A1 · Procter · 2020 [cited by applicant]
US 20200038545A1 · Procter · 2020 [cited by applicant]
CN 101014376A · 2007 [cited by applicant]
WO WO2006041365 · 2006 [cited by applicant]
WO WO2016196371 · 2016 [cited by applicant]
WO WO2018060287 · 2018 [cited by applicant]
Coppey E, et al;. “Early Complications From the Use of Calcium Phosphate Paste in Mandibular Lengthening Surgery. A Retrospective Study” J Oral Maxillofac Surg. 2017;75(6):1274.e1-1274.e10. doi:10.1016/j.joms.2017.01.01… [cited by applicant]
Correa et al., “α-Tricalcium phosphate cements modified with β-dicalcium silicate and tricalcium aluminate: Physicochemical characterization, in vitro bioactivity and cytotoxicity”, J. Biomedical Materials Research B: A… [cited by applicant]
Dorozhkin, “Calcium orthophosphate-based biocomposites and hybrid biomaterials”, J Mater Sci (2009) 44:2343-2387. [cited by applicant]
Duan, et al., “Applications of Bioadhesives: A Mini Review”, Frontiers in Bioengineering and Biotechnology, Sep. 2021 vol. 9:7; 1-12. [cited by applicant]
Ge, et al., “Review: Recent Advances in Tissue Adhesives for Clinical Medicine”, Polymers, (2020) 12:939 p. 1-22. [cited by applicant]
HexArmor, “Concrete irritation, Burns, and dermatitis”, Retrieved Aug. 26, 2022, from https://www.hexarmor.com/posts/concrete-irritation-burns-and-dermatitis. [cited by applicant]
International Search report for PCT/EP2017/074551, dated Dec. 13, 2017, 3 pages. [cited by applicant]
International Search report for PCT/EP2017/074553, dated Dec. 13, 2017, 3 pages. [cited by applicant]
Li, et al., “Ability of Obturation Materials to Improve the Seal of the Root Canal System—a Review”, Acta Biomater. (2014) 10(3): pp. 1050-1063. [cited by applicant]
Morejon-Alonso et al., “Effects of Silica Addition on the Chemical, Mechanical and Biological Properties of a New α-Tricalcium Phosphate/Tricalcium Silicate Cement”, Materials Research, 2011, 14(4): 475-482. [cited by applicant]
Mostafa et al., “Injectable Bone Cement Based on Calcium Silicate and Calcium Phosphate”, Int. J. Chem. Sci.: 13(1), 2015: 80-96. [cited by applicant]
Motisuke et al., “Apatite bone cement reinforced with calcium silicate fibers”, J. Mater Sci: Mater Med (2014) 25:2357-2363. [cited by applicant]
NPL search for “phosphoserine” in PubChem; downloaded May 1, 2020. [cited by applicant]
Office Action issued for CN 201780059294.7 dated Apr. 6, 2021 (w/English translation) 21 pgs. [cited by applicant]
Office Action issued for U.S. Appl. No. 16/337,355 dated May 26, 2022, 8 pages. [cited by applicant]
Office Action issued for U.S. Appl. No. 16/337,355 dated Aug. 2, 2022, 18 pages. [cited by applicant]
Office Action issued for U.S. Appl. No. 16/337,355 dated Jan. 5, 2023, 13 pages. [cited by applicant]
Office Action issued for U.S. Appl. No. 16/337,355 dated Aug. 1, 2023, 18 pages. [cited by applicant]
Office Action issued for U.S. Appl. No. 16/337,355 dated Mar. 12, 2024, 15 pages. [cited by applicant]
Schneiders et al., “Effect of modification of hydroxyapatite/collagen composites with sodium citrate, phosphoserine, phosphoserine/RGD-peptide and calcium carbonate on bone remodeling”, Bone 40 (2007): 1048-1059. [cited by applicant]
van Loghem J, et al., “Managing intravascular complications following treatment with calcium hydroxylapatite: An expert consensus” J Cosmet Dermatol. 2020;19(11):2845-2858. doi:10.1111/jocd.13353. [cited by applicant]